Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Predominantly third-line pancreatic cancer patients showed durable survival despite advanced disease, and the patient treated with Namodenoson as second-line therapy remains alive more than 18 months. The report is a positive early clinical signal but does not indicate broad efficacy across the wider population.

Analysis

Predominantly third-line pancreatic cancer patients showed durable survival despite advanced disease, and the patient treated with Namodenoson as second-line therapy remains alive more than 18 months. The report is a positive early clinical signal but does not indicate broad efficacy across the wider population.